Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

. The March 2013 notes reflecting 10.4 million shares are excluded from the non-GAAP diluted earnings per share for the 2009 periods presented as their impact is considered anti-dilutive.

Conference Call Details

BioMarin will host a conference call and webcast to discuss third quarter 2009 financial results today, Wednesday, October 28, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

    Date: October 28, 2009
    Time: 5:00 p.m. ET
    U.S. / Canada Dial-in Number:  800.299.6183
    International Dial-in Number:  617.801.9713
    Participant Code: 51404008
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 51416825

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Datameer announced today that Cardinal Health ... on their big data platform. Datameer gives Cardinal ... to quickly and easily visualize and understand data ... 19 company, Cardinal Health is one of the ... and medical products to more than 60,000 locations ...
(Date:5/23/2013)... -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), ... and commercialization of novel bile acid therapeutics to treat ... announced that Mark Pruzanski , MD, ... Deutsche Bank Securities 38th Annual Health Care Conference in ... 2013 at 4:10 p.m. ET. About Intercept ...
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
Breaking Medicine Technology:Cardinal Health Selects Datameer for Healthcare Data Discovery 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... Relationship, BOCA RATON, Fla., June 25, 2007 /PRNewswire/ ... more than half of women whose male,partners have ... incorrectly attribute them to the normal course of,aging. ... their male,partner's symptoms of low testosterone negatively impact ...
... Glucose Homeostasis Effects in,Normal and Diabetic Rats --, ... 14-day,Phase IIa study of the safety profile of ... inhibitor of,the Sodium-Glucose Transporter 2 (SGLT2) administered alone ... diabetes, no,discontinuations due to adverse events and no ...
Cached Medicine Technology:New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 2New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 3New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 4New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6
(Date:5/24/2013)... May 24, 2013 For the second ... Braeda Fresh Express Café to treat Tabitha Meals on ... to their door. More than 400 meal recipients recently ... the restaurants, along with the rest of a well-balanced, ... proud to partner with the Tabitha Meals on Wheels ...
(Date:5/24/2013)... The Lap Band Center now offers complementary ... Madan, head doctor at The Lap Band Center, if ... a change for the better, it is time to consider ... the risks that come with obesity and one way to ... healthily. , Obesity related diseases are no laughing matter, ...
(Date:5/24/2013)... Wednesday, 15th May 2013 | 10am BST | 5pm HKT ... http://bit.ly/10Rt0ZH , Ongoing regulatory changes are likely to ... and particularly in Europe, a number of these new regulatory ... dealmakers, understanding how the likes of Basel iii, Solvency II, ... of the market will give you a competitive edge and ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Scott Ryan ... brother, Troy Tischler, lose 200 lbs. of fat in ... Tischler teach his younger brother the importance of exercising. ... diet. By sticking to these 7 rules of healthy ... loss goals can be accomplished. , 1.    Find a distraction ...
(Date:5/23/2013)... 24, 2013 Magnatag’s new magnetic 365-Day ... and reduces vacation conflicts. A Manufacturing Manager from Augusta ... conflicts; now employees and managers can check the board ... Attendance is important to us and the board makes ... may seem harsh but it has made a difference.” ...
Breaking Medicine News(10 mins):Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:The Lap Band Center Announces That They Offer Complementary Consultation for First Time Patients 2Health News:The Lap Band Center Announces That They Offer Complementary Consultation for First Time Patients 3Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2
... proposed to initiate mass-production of a live bird flu vaccine ... the start of next year // in China. This ... a vaccine for humans. ,More than 1-billion ... the year-end. This would be a supplement to the already ...
... waves had left over 25,000 people dead and many more ... Indian Ocean countries. // One in five Thai ... that forever changed the physical, social and psychological landscape of ... interviews, an average of 20 percent of Thai tsunami survivors ...
... will make women more empowered. They have now developed ... completely.,The pill developed by New Jersey-based Wyeth and called ... and the inconvenience of periods. ,Critics have warned ... and breast cancer. They said continuous exposure to hormones ...
... give a false picture about coma survival and recovery rates ... felt // by coma patients and found that the ... not true as the study show that only 8% of ... with 50% upwards in real life. ,The recovery ...
... by researchers at Washington University School of Medicine in St. ... rapidly after treatment and are not as depressed as some ... of this study appear in the December issue of Supportive ... underwent radiation therapy at Siteman Cancer Center at Washington University ...
... picture of coma patients' survival and recovery, with potentially important ... storylines containing coma patients over 10 years, researchers found that ... coma than in real life. And they were also much ... of soap land patients died during coma, compared with over ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: